Selection and evolution of disulfide-rich peptides via cellular protein quality control

Xiaoting Meng, Chaoying Xu, Shihui Fan, Meng Dong, Jie Zhuang, Zengping Duan, Yibing Zhao and Chuanliu Wu

Chem. Sci., 2023, 14, 3668
DOI: 10.1039/D2SC05343H

Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

Hao-Peng Sun, Zheng-Yu Jiang, Ming-Ye Zhang, Meng-Chen Lu, Ting-Ting Yang, Yang Pan, Hao-Ze Huang, Xiao-Jin Zhang and Qi-dong You

Med. Chem. Commun., 2014, 5, 93
DOI: 10.1039/C3MD00240C

Structural investigation of Keap1–Nrf2 protein–protein interaction (PPI) inhibitors for treating myocarditis through molecular simulations

Yan Tuo, Yuelu Tang, Yongxin Yu, Haoran Liang, Bin Huang, Shan Geng and Yuanqiang Wang

New J. Chem., 2023, 47, 8524
DOI: 10.1039/D2NJ03078K

Small molecules inhibiting Keap1–Nrf2 protein–protein interactions: a novel approach to activate Nrf2 function

Chunlin Zhuang, Zhongli Wu, Chengguo Xing and Zhenyuan Miao

Med. Chem. Commun., 2017, 8, 286
DOI: 10.1039/C6MD00500D

A phage display-based strategy for the de novo creation of disulfide-constrained and isomer-free bicyclic peptide affinity reagents

Mirao Zha, Ping Lin, Hongwei Yao, Yibing Zhao and Chuanliu Wu

Chem. Commun., 2018, 54, 4029
DOI: 10.1039/C7CC09142G

A cell-active cyclic peptide targeting the Nrf2/Keap1 protein–protein interaction

Jessica Iegre, Sona Krajcovicova, Anders Gunnarsson, Lisa Wissler, Helena Käck, Anna Luchniak, Stefan Tångefjord, Frank Narjes and David R. Spring

Chem. Sci., 2023, 14, 10800
DOI: 10.1039/D3SC04083F

Cyclo(-Phe-Phe) alleviates chick embryo liver injuryviaactivating the Nrf2 pathway

Qiong-Yi Zhang, Shao-Cong Han, Rong-Ping Huang, Man-Ya Jiang, Chang-Yu Yan, Xi-You Li, Yu-Jiao Zhan, Xiao-Min Li, Yi-Fang Li, Hiroshi Kurihara, Rui-Rong Tan, Wei-Xi Li and Rong-Rong He

Food Funct., 2022, 13, 6962
DOI: 10.1039/D2FO00674J

Fragment-growing guided design of Keap1-Nrf2 protein-protein interaction inhibitors for targeting myocarditis

Ning Meng, Hua Tang, Hao Zhang, Chengshi Jiang, Li Su, Xiao Min, Wannian Zhang, Hua Zhang, Zhenyuan Miao, Wen Zhang and Chunlin Zhuang

Free Radical Biology and Medicine, 2018, 117, 228
DOI: 10.1016/j.freeradbiomed.2018.02.010

Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction

Stefania Colarusso, Daniele De Simone, Tommaso Frattarelli, Matteo Andreini, Mauro Cerretani, Antonino Missineo, Daniele Moretti, Sara Tambone, Georg Kempf, Martin Augustin, Stefan Steinbacher, Ignacio Munoz-Sanjuan, Larry Park, Vincenzo Summa, Licia Tomei, Alberto Bresciani, Celia Dominguez, Leticia Toledo-Sherman and Elisabetta Bianchi

Bioorganic & Medicinal Chemistry, 2020, 28, 115738
DOI: 10.1016/j.bmc.2020.115738

The Keap1–Nrf2 protein–protein interaction: A suitable target for small molecules

Dieter Schmoll, Christian K. Engel and Heiner Glombik

Drug Discovery Today: Technologies, 2017, 24, 11
DOI: 10.1016/j.ddtec.2017.10.001

Nrf2/Keap1/ARE signaling: Towards specific regulation

Alexey V. Ulasov, Andrey A. Rosenkranz, Georgii P. Georgiev and Alexander S. Sobolev

Life Sciences, 2022, 291, 120111
DOI: 10.1016/j.lfs.2021.120111

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Duncan E. Scott, Andrew R. Bayly, Chris Abell and John Skidmore

Nat Rev Drug Discov, 2016, 15, 533
DOI: 10.1038/nrd.2016.29

Noncellular screening for the discovery of protein–protein interaction modulators

Charline Kieffer, Jean Pierre Jourdan, Marie Jouanne and Anne Sophie Voisin-Chiret

Drug Discovery Today, 2020, 25, 1592
DOI: 10.1016/j.drudis.2020.07.012

Solid-Phase Synthesis of Triostin A Using a Symmetrical Bis(diphenylmethyl) Linker System

Ganesh A. Sable and Dongyeol Lim

J. Org. Chem., 2015, 80, 7486
DOI: 10.1021/acs.joc.5b01055

Modified Peptide Inhibitors of the Keap1–Nrf2 Protein–Protein Interaction Incorporating Unnatural Amino Acids

Nikolaos D. Georgakopoulos, Sandeep K. Talapatra, Jemma Gatliff, Frank Kozielski and Geoff Wells

ChemBioChem, 2018, 19, 1810
DOI: 10.1002/cbic.201800170

Involvement of Nrf2 and Keap1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent peptides from soft-shelled turtle

Nan Wang, Wei Wang, Faizan Ahmed Sadiq, Shilei Wang, Liu Caiqin and Jin Jianchang

Process Biochemistry, 2020, 92, 174
DOI: 10.1016/j.procbio.2019.12.022

Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode

Nikolaos Georgakopoulos, Sandeep Talapatra, Dina Dikovskaya, Sharadha Dayalan Naidu, Maureen Higgins, Jemma Gatliff, Aysel Ayhan, Roxani Nikoloudaki, Marjolein Schaap, Klara Valko, Farideh Javid, Albena T. Dinkova-Kostova, Frank Kozielski and Geoffrey Wells

J. Med. Chem., 2022, 65, 7380
DOI: 10.1021/acs.jmedchem.2c00457

Polar Recognition Group Study of Keap1-Nrf2 Protein–Protein Interaction Inhibitors

Meng-Chen Lu, Shi-Jie Tan, Jian-Ai Ji, Zhi-Yun Chen, Zhen-Wei Yuan, Qi-Dong You and Zheng-Yu Jiang

ACS Med. Chem. Lett., 2016, 7, 835
DOI: 10.1021/acsmedchemlett.5b00407

Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach

Antonio Cuadrado, Gina Manda, Ahmed Hassan, María José Alcaraz, Coral Barbas, Andreas Daiber, Pietro Ghezzi, Rafael León, Manuela G. López, Baldo Oliva, Marta Pajares, Ana I. Rojo, Natalia Robledinos-Antón, Angela M. Valverde, Emre Guney and Harald H.H.W. Schmidt

Pharmacological Reviews, 2018, 70, 348
DOI: 10.1124/pr.117.014753

Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives

Yangguo Zhou, Qiong Zhang, Ziquan Zhao, Xiuqi Hu, Qidong You and Zhengyu Jiang

European Journal of Medicinal Chemistry, 2024, 269, 116270
DOI: 10.1016/j.ejmech.2024.116270

Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish

Azhwar Raghunath, Raju Nagarajan, Kiruthika Sundarraj, Kavipriya Palanisamy and Ekambaram Perumal

Basic Clin Pharma Tox, 2019, 125, 259
DOI: 10.1111/bcpt.13222

Development of Keap1-interactive small molecules that regulate Nrf2 transcriptional activity

Nikolaos D. Georgakopoulos, Jemma Gatliff and Geoff Wells

Current Opinion in Toxicology, 2016, 1, 1
DOI: 10.1016/j.cotox.2016.08.002

Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis

Ke Chen, Liuliu Huang and Bin Shen

Biophysical Chemistry, 2019, 244, 22
DOI: 10.1016/j.bpc.2018.11.002

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Haiying Lu, Qiaodan Zhou, Jun He, Zhongliang Jiang, Cheng Peng, Rongsheng Tong and Jianyou Shi

Sig Transduct Target Ther, 2020, 5
DOI: 10.1038/s41392-020-00315-3

An Integrated Molecular Grafting Approach for the Design of Keap1-Targeted Peptide Inhibitors

Huawu Yin, Yen-Hua Huang, Sarah A. Best, Kate D. Sutherland, David J. Craik and Conan K. Wang

ACS Chem. Biol., 2021, 16, 1276
DOI: 10.1021/acschembio.1c00388

Modulators of Protein–Protein Interactions

Lech-Gustav Milroy, Tom N. Grossmann, Sven Hennig, Luc Brunsveld and Christian Ottmann

Chem. Rev., 2014, 114, 4695
DOI: 10.1021/cr400698c

Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present)

Haishan Zhou, Yan Wang, Qidong You and Zhengyu Jiang

Expert Opinion on Therapeutic Patents, 2020, 30, 209
DOI: 10.1080/13543776.2020.1715365

Buyang Huanwu decoction alleviates oxidative injury of cerebral ischemia-reperfusion through PKCε/Nrf2 signaling pathway

Meijuan Yin, Zhenyi Liu, Jing Wang and Weijuan Gao

Journal of Ethnopharmacology, 2023, 303, 115953
DOI: 10.1016/j.jep.2022.115953

Engineering a genetically encoded competitive inhibitor of the KEAP1–NRF2 interaction via structure-based design and phage display

Gurkan Guntas, Steven M. Lewis, Kathleen M. Mulvaney, Erica W. Cloer, Ashutosh Tripathy, Thomas R. Lane, Michael B. Major and Brian Kuhlman

Protein Engineering, Design and Selection, 2015, gzv055
DOI: 10.1093/protein/gzv055

PinaColada: peptide–inhibitor ant colony ad-hoc design algorithm

Daniel Zaidman and Haim J. Wolfson

Bioinformatics, 2016, 32, 2289
DOI: 10.1093/bioinformatics/btw133

Discovery of Potent Keap1–Nrf2 Protein–Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis

Zheng-Yu Jiang, Meng-Chen Lu, Li−Li Xu, Ting-Ting Yang, Mei-Yang Xi, Xiao-Li Xu, Xiao-Ke Guo, Xiao-Jin Zhang, Qi-Dong You and Hao-Peng Sun

J. Med. Chem., 2014, 57, 2736
DOI: 10.1021/jm5000529

Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction

Richard J. Steel, Maria A. O'Connell and Mark Searcey

Bioorganic & Medicinal Chemistry Letters, 2018, 28, 2728
DOI: 10.1016/j.bmcl.2018.03.003

Development of a steady‐state FRET‐based assay to identify inhibitors of the Keap1‐Nrf2 protein–protein interaction

Marjolein Schaap, Rowena Hancock, Andrew Wilderspin and Geoff Wells

Protein Science, 2013, 22, 1812
DOI: 10.1002/pro.2384

Exploring new strategies for grafting binding peptides onto protein loops using a consensus‐designed tetratricopeptide repeat scaffold

Sarah K. Madden, Albert Perez‐Riba and Laura S. Itzhaki

Protein Science, 2019, 28, 738
DOI: 10.1002/pro.3586

Peptide Macrocycles Developed from Precisely Regulated Multiple Cyclization of Unprotected Peptides

Jinghui Wang, Mirao Zha, Qianran Fei, Weidong Liu, Yibing Zhao and Chuanliu Wu

Chemistry A European J, 2017, 23, 15150
DOI: 10.1002/chem.201703139

Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions

Meng-Chen Lu, Hong-Li Shao, Tian Liu, Qi-Dong You and Zheng-Yu Jiang

European Journal of Medicinal Chemistry, 2020, 207, 112734
DOI: 10.1016/j.ejmech.2020.112734

Identification of novel Nrf2 activators from Cinnamomum chartophyllum H.W. Li and their potential application of preventing oxidative insults in human lung epithelial cells

Ming-Xing Zhou, Guo-Hui Li, Bin Sun, You-Wei Xu, Ai-Ling Li, Yan-Ru Li, Dong-Mei Ren, Xiao-Ning Wang, Xue-Sen Wen, Hong-Xiang Lou and Tao Shen

Redox Biology, 2018, 14, 154
DOI: 10.1016/j.redox.2017.09.004

Canonical and non-canonical mechanisms of Nrf2 activation

Carlos Alfredo Silva-Islas and Perla D. Maldonado

Pharmacological Research, 2018, 134, 92
DOI: 10.1016/j.phrs.2018.06.013

Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway

B.G. Richardson, A.D. Jain, T.E. Speltz and T.W. Moore

Bioorganic & Medicinal Chemistry Letters, 2015, 25, 2261
DOI: 10.1016/j.bmcl.2015.04.019

Peptide and small molecule inhibitors of the Keap1–Nrf2 protein–protein interaction

Geoff Wells

Biochemical Society Transactions, 2015, 43, 674
DOI: 10.1042/BST20150051

Computational Prediction of Cyclic Peptide Structural Ensembles and Application to the Design of Keap1 Binders

Francini Fonseca Lopez, Jiayuan Miao, Jovan Damjanovic, Luca Bischof, Michael B. Braun, Yingjie Ling, Marcus D. Hartmann, Yu-Shan Lin and Joshua A. Kritzer

J. Chem. Inf. Model., 2023, 63, 6925
DOI: 10.1021/acs.jcim.3c01337

KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

Enrique Crisman, Pablo Duarte, Esteban Dauden, Antonio Cuadrado, María Isabel Rodríguez‐Franco, Manuela G. López and Rafael León

Medicinal Research Reviews, 2023, 43, 237
DOI: 10.1002/med.21925

Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions

Zheng-Yu Jiang, Meng-Chen Lu and Qi-Dong You

J. Med. Chem., 2016, 59, 10837
DOI: 10.1021/acs.jmedchem.6b00586

Mitochondrial protective effect of neferine through the modulation of nuclear factor erythroid 2‐related factor 2 signalling in ischaemic stroke

Chuanhong Wu, Jianxin Chen, Ruocong Yang, Feipeng Duan, Shaojing Li and Xiuping Chen

British J Pharmacology, 2019, 176, 400
DOI: 10.1111/bph.14537

New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases

Peter Canning and Alex N. Bullock

Biochemical Society Transactions, 2014, 42, 103
DOI: 10.1042/BST20130215

Discovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agents

Dhulfiqar Ali Abed, Melanie Goldstein, Haifa Albanyan, Huijuan Jin and Longqin Hu

Acta Pharmaceutica Sinica B, 2015, 5, 285
DOI: 10.1016/j.apsb.2015.05.008

Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Protein–Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity

Meng-Chen Lu, Xian Zhang, Feng Wu, Shi-Jie Tan, Jing Zhao, Qi-Dong You and Zheng-Yu Jiang

J. Med. Chem., 2019, 62, 6796
DOI: 10.1021/acs.jmedchem.9b00818

Dual-functional alginate crosslinker: Independent control of crosslinking density and cell adhesive properties of hydrogels via separate conjugation pathways

Cholong Choi, Suntae Kim and Chaenyung Cha

Carbohydrate Polymers, 2021, 252, 117128
DOI: 10.1016/j.carbpol.2020.117128

Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1–Nrf2 Protein–Protein Interaction

Hélène C. Bertrand, Marjolein Schaap, Liam Baird, Nikolaos D. Georgakopoulos, Adrian Fowkes, Clarisse Thiollier, Hiroko Kachi, Albena T. Dinkova-Kostova and Geoff Wells

J. Med. Chem., 2015, 58, 7186
DOI: 10.1021/acs.jmedchem.5b00602

Comprehensive analysis of loops at protein-protein interfaces for macrocycle design

Jason Gavenonis, Bradley A Sheneman, Timothy R Siegert, Matthew R Eshelman and Joshua A Kritzer

Nat Chem Biol, 2014, 10, 716
DOI: 10.1038/nchembio.1580

The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases

Prashant Deshmukh, Sruthi Unni, Gopinatha Krishnappa and Balasundaram Padmanabhan

Biophys Rev, 2017, 9, 41
DOI: 10.1007/s12551-016-0244-4

Design and Synthesis of Cross-Link-Dense Peptides by Manipulating Regioselective Bisthioether Cross-Linking and Orthogonal Disulfide Pairing

Huilei Dong, Xiaoting Meng, Xiaoli Zheng, Xueting Cheng, Yiwu Zheng, Yibing Zhao and Chuanliu Wu

J. Org. Chem., 2019, 84, 5187
DOI: 10.1021/acs.joc.9b00164

MOrPH-PhD: An Integrated Phage Display Platform for the Discovery of Functional Genetically Encoded Peptide Macrocycles

Andrew E. Owens, Jacob A. Iannuzzelli, Yu Gu and Rudi Fasan

ACS Cent. Sci., 2020, 6, 368
DOI: 10.1021/acscentsci.9b00927

Fast and Selective Reaction of 2-Benzylacrylaldehyde with 1,2-Aminothiol for Stable N-Terminal Cysteine Modification and Peptide Cyclization

Yaqi Wu, Cong Li, Shihui Fan, Yibing Zhao and Chuanliu Wu

Bioconjugate Chem., 2021, 32, 2065
DOI: 10.1021/acs.bioconjchem.1c00378

Inhibiting the Keap1/Nrf2 Protein‐Protein Interaction with Protein‐Like Polymers

Kendal P. Carrow, Haylee L. Hamilton, Madeline P. Hopps, Yang Li, Baofu Qiao, N. Connor Payne, Matthew P. Thompson, Xiaoyu Zhang, Assa Magassa, Mara Fattah, Shivangi Agarwal, Michael P. Vincent, Marina Buyanova, Paul A. Bertin, Ralph Mazitschek, Monica Olvera de la Cruz, Delinda A. Johnson, Jeffrey A. Johnson and Nathan C. Gianneschi

Advanced Materials, 2024, 36
DOI: 10.1002/adma.202311467

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors

Hai-Shan Zhou, Lv-Bin Hu, Han Zhang, Wen-Xin Shan, Yan Wang, Xue Li, Tian Liu, Jing Zhao, Qi-Dong You and Zheng-Yu Jiang

J. Med. Chem., 2020, 63, 11149
DOI: 10.1021/acs.jmedchem.0c01116

The mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding

Ranko Gacesa, Karl P. Lawrence, Nikolaos D. Georgakopoulos, Kazuo Yabe, Walter C. Dunlap, David J. Barlow, Geoffrey Wells, Antony R. Young and Paul F. Long

Biochimie, 2018, 154, 35
DOI: 10.1016/j.biochi.2018.07.020

PROTEIN-PROTEIN INTERACTION ANALYSIS TO IDENTIFY NUCLEAR FACTOR-ERYTHROID-2 FACTOR 2 (NRF2) INHIBITION BY EXTRACELLULAR ENZYMES FROM WATER KEFIR ORGANISMS

WIDHYA ALIGITA, MARLIA SINGGIH, ENTRIS SUTRISNO and I. KETUT ADNYANA

Int J App Pharm, 2023, 109
DOI: 10.22159/ijap.2023.v15s2.20

Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches

Alessandra Monti, Luigi Vitagliano, Andrea Caporale, Menotti Ruvo and Nunzianna Doti

IJMS, 2023, 24, 7842
DOI: 10.3390/ijms24097842

Emerging Screening Approaches in the Development of Nrf2–Keap1 Protein–Protein Interaction Inhibitors

Chung-Hang Leung, Jia-Tong Zhang, Guan-Jun Yang, Hao Liu, Quan-Bin Han and Dik-Lung Ma

IJMS, 2019, 20, 4445
DOI: 10.3390/ijms20184445

Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors

Yi Mou, Shuai Wen, Yu-Xiu Li, Xin-Xing Gao, Xin Zhang and Zheng-Yu Jiang

European Journal of Medicinal Chemistry, 2020, 202, 112532
DOI: 10.1016/j.ejmech.2020.112532

Molecular dynamics, quantum mechanics and docking studies of some Keap1 inhibitors – An insight into the atomistic mechanisms of their antioxidant potential

Temitope Isaac Adelusi, Misbaudeen Abdul-Hammed, Mukhtar Oluwaseun Idris, Qudus Kehinde Oyedele and Ibrahim Olaide Adedotun

Heliyon, 2021, 7, e07317
DOI: 10.1016/j.heliyon.2021.e07317

Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages

Larissa Staurengo-Ferrari, Stephanie Badaro-Garcia, Miriam S. N. Hohmann, Marília F. Manchope, Tiago H. Zaninelli, Rubia Casagrande and Waldiceu A. Verri

Front. Pharmacol., 2019, 9
DOI: 10.3389/fphar.2018.01536

Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress

Jing Chen, Disheng Feng, Rui Zhu, Hua Li and Lixia Chen

Redox Biology, 2025, 85, 103781
DOI: 10.1016/j.redox.2025.103781

Structural basis of Nrf2 activation by flavonolignans from silymarin

Martiniano Bello

Journal of Molecular Graphics and Modelling, 2023, 119, 108393
DOI: 10.1016/j.jmgm.2022.108393

Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway

Ludovic J. Deny, Hussein Traboulsi, André M. Cantin, Éric Marsault, Martin V. Richter and Guillaume Bélanger

J. Med. Chem., 2016, 59, 9431
DOI: 10.1021/acs.jmedchem.6b01132

Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency

Meng-Chen Lu, Qiong Jiao, Tian Liu, Shi-Jie Tan, Hai-Shan Zhou, Qi-Dong You and Zheng-Yu Jiang

European Journal of Medicinal Chemistry, 2018, 143, 1578
DOI: 10.1016/j.ejmech.2017.10.052

Crystallography-Guided Optimizations of the Keap1–Nrf2 Inhibitors on the Solvent Exposed Region: From Symmetric to Asymmetric Naphthalenesulfonamides

Guodong Liu, Ruilin Hou, Lijuan Xu, Xinqi Zhang, Jianyu Yan, Chengguo Xing, Ke Xu and Chunlin Zhuang

J. Med. Chem., 2022, 65, 8289
DOI: 10.1021/acs.jmedchem.2c00170

Identification and characterisation of a G-quadruplex forming sequence in the promoter region of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)

Zoë A.E. Waller, Lesley A. Howell, Colin J. MacDonald, Maria A. O’Connell and Mark Searcey

Biochemical and Biophysical Research Communications, 2014, 447, 128
DOI: 10.1016/j.bbrc.2014.03.117

Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease

Fiona Kerr, Oyinkan Sofola-Adesakin, Dobril K. Ivanov, Jemma Gatliff, Beatriz Gomez Perez-Nievas, Hélène C. Bertrand, Pedro Martinez, Rebecca Callard, Inge Snoeren, Helena M. Cochemé, Jennifer Adcott, Mobina Khericha, Jorge Iván Castillo-Quan, Geoffrey Wells, Wendy Noble, Janet Thornton, Linda Partridge and Bingwei Lu

PLoS Genet, 2017, 13, e1006593
DOI: 10.1371/journal.pgen.1006593

Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development

Natalia Robledinos-Antón, Raquel Fernández-Ginés, Gina Manda and Antonio Cuadrado

Oxidative Medicine and Cellular Longevity, 2019, 2019, 1
DOI: 10.1155/2019/9372182

Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex

Martiniano Bello and José Antonio Morales-González

International Journal of Biological Macromolecules, 2017, 105, 981
DOI: 10.1016/j.ijbiomac.2017.07.117

Novel diterpenoid-type activators of the Keap1/Nrf2/ARE signaling pathway and their regulation of redox homeostasis

Ai-Ling Li, Tao Shen, Tian Wang, Ming-Xing Zhou, Bin Wang, Jin-Tong Song, Peng-Liang Zhang, Xiao-Ling Wang, Dong-Mei Ren, Hong-Xiang Lou and Xiao-Ning Wang

Free Radical Biology and Medicine, 2019, 141, 21
DOI: 10.1016/j.freeradbiomed.2019.06.001

Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1–Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases

Jakob S. Pallesen, Kim T. Tran and Anders Bach

J. Med. Chem., 2018, 61, 8088
DOI: 10.1021/acs.jmedchem.8b00358

Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery

Sarah K. Madden and Laura S. Itzhaki

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2020, 1868, 140405
DOI: 10.1016/j.bbapap.2020.140405

Pharmacological characterization of a novel peptide inhibitor of the Keap1-Nrf2 protein-protein interaction

Mònica Aparici, Mònica Bravo, Elena Calama, Vicente García-González, Teresa Domènech, Mònica Córdoba, Inés Roger, Julio Cortijo, Miriam Góngora-Benítez, Marta Paradís-Bas, Barry Collins, Andrew M. Davis, Fernando Albericio and Carlos Puig

Biochemical Pharmacology, 2022, 204, 115226
DOI: 10.1016/j.bcp.2022.115226